| 14.68 0.52 (3.67%) | 08-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.48 |
1-year : | 21.59 |
| Resists | First : | 15.82 |
Second : | 18.48 |
| Pivot price | 14.45 |
|||
| Supports | First : | 13.87 |
Second : | 12.65 |
| MAs | MA(5) : | 14.17 |
MA(20) : | 14.23 |
| MA(100) : | 15.72 |
MA(250) : | 14.39 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 44.9 |
D(3) : | 42  |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 19.6 | Low : | 8.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NPCE ] has closed below upper band by 33.9%. Bollinger Bands are 50.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.88 - 14.94 | 14.94 - 15 |
| Low: | 13.98 - 14.05 | 14.05 - 14.11 |
| Close: | 14.57 - 14.68 | 14.68 - 14.78 |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Wed, 26 Aug 2026
NeuroPace Inc (NPCE) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Sun, 23 Aug 2026
Deutsche Bank AG Acquires Shares of 938,919 NeuroPace, Inc. $NPCE - MarketBeat
Fri, 21 Aug 2026
Neuropace Inc (NASDAQ: NPCE) Share Price, NPCE Stock News, NPCE Share Price & Updates - kalkine.ca
Mon, 17 Aug 2026
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - TradingView
Mon, 17 Aug 2026
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 34 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 93.9 (%) |
| Shares Short | 822 (K) |
| Shares Short P.Month | 899 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -17.9 % |
| Operating Margin | -22.6 % |
| Return on Assets (ttm) | -7.5 % |
| Return on Equity (ttm) | -103.3 % |
| Qtrly Rev. Growth | 17.1 % |
| Gross Profit (p.s.) | 2.41 |
| Sales Per Share | 3.11 |
| EBITDA (p.s.) | -0.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -31.24 |
| PEG Ratio | 0 |
| Price to Book value | 41.94 |
| Price to Sales | 4.7 |
| Price to Cash Flow | -44.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|